Phase 2 N=63 Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
Colorectal Cancer
Primary: Median Time for Progression Free Survival — 15.8 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 N-Acetyl Cysteine in Trichotillomania
Trichotillomania
Primary: Massachusetts General Hospital Hairpulling Scale — 17.6; 16.7; 10.4; 16.0 units on a scale
Phase 2 N=38 CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Leukemia
Primary: Overall Response Rate (ORR) — 37 percentage of participants
Phase 2 N=50 Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: Progression Free Survival (PFS) — 11 months
Phase 2 N=39 Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis
Multiple Sclerosis · Depression
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) — 45.5; 47.4 percentage of subjects
Phase 2 N=4 Study of Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Children With Autism
Autism
Primary: Extent of Absorption of Memantine (Part One) — 682.53 ng•h/mL
Phase 2 N=10 Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Brain and Central Nervous System Tumors
Primary: Number of Patients Surviving Without Disease Progression After 6 Months — 0 participants
Phase 2 N=33 Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma
Primary: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen — 0; 5; 28 participants
Phase 2 N=198 Feasibility of Delphi Screener for Cervical Cytology
Cervical Neoplasia
Primary: Sensitivity and Specificity — 0.86; 0.80 % of participants correctly diagnosed
Phase 2 N=98 Ondansetron Versus Aprepitant Plus Ondansetron for Emesis
Hematologic Diseases · Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Participant Responses — 20; 21; 9; 12 participants
Phase 2 N=227 Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Rheumatoid Arthritis Erosion Score Measured From MRI Assessments (RA-MRI ES) at Month 6 — 0.00; 0.00; 0.49 units on a scale — p=0.264
Phase 2 N=218 Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
Graft Rejection · Kidney Transplantation · Renal Transplantation
Primary: Number of Participants With an Episode of Clinically-suspected and Biopsy-proven Acute Rejection (CSPAR) — 5; 4; 6 Participants
Phase 2 N=11 Oral T7 Oral Testosterone in Man
Healthy Males · Male Contraceptive
Primary: Maximum Testosterone Concentration — 471; 444; 543 ng*hr/dL
Phase 2 N=127 Robotic Assisted Upper-Limb Neurorehabilitation in Stroke Patients
Stroke
Primary: Fugl-Meyer Assessment for Motor Recovery (FM) Scale — 3.01; 3.19; -2.08; 3.87 units on a scale — p=0.08
Phase 2 N=24 Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
Epilepsy
Primary: Seizure Frequency — 0.655; 0.435; 0.631 Seizures per Day